PNC Financial Services Group’s Palvella Therapeutics PVLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.66K Buy
41
+10
+32% +$1.48K ﹤0.01% 4452
2026
Q2
$4.74K Buy
31
+1
+3% +$121 ﹤0.01% 4411
2026
Q1
$3.74K Hold
30
– – ﹤0.01% 4391
2025
Q4
$3.14K Buy
30
+20
+200% +$1.71K ﹤0.01% 4405
2025
Q3
$627 Buy
+10
New +$446 ﹤0.01% 4761
2020
Q1
– Sell
-13
Closed -$4K – 4073
2019
Q4
$4K Hold
13
– – ﹤0.01% 3708
2019
Q3
$3K Hold
13
– – ﹤0.01% 3830
2019
Q2
$5K Hold
13
– – ﹤0.01% 3752
2019
Q1
$3K Hold
13
– – ﹤0.01% 3840
2018
Q4
$3K Hold
13
– – ﹤0.01% 3816
2018
Q3
$6K Hold
13
– – ﹤0.01% 3800
2018
Q2
$5K Hold
13
– – ﹤0.01% 3850
2018
Q1
$7K Buy
+13
New +$8.05K ﹤0.01% 3834

Other funds holding PVLA

PNC Financial Services Group's PVLA Position: Q3 2026 in Review

PNC Financial Services Group increased its Palvella Therapeutics (PVLA) stake by 32% in Q3 2026, buying an estimated $1.48K and bringing the position to 41 shares worth $5.66K. The position accounts for ﹤0.01% of the portfolio, ranked #4452.

PNC Financial Services Group first reported a position in PVLA in Q1 2018 and has held it in 13 quarters since. The position peaked at $7K in Q1 2018. 199 funds tracked by Wall St. Rank hold PVLA as of Q3 2026.

  • PNC Financial Services Group held 41 shares of Palvella Therapeutics worth $5.66K as of Q3 2026.
  • PNC Financial Services Group bought 10 Palvella Therapeutics shares in Q3 2026, an estimated $1.48K.
  • Palvella Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #4452 holding.
  • PNC Financial Services Group first reported a position in Palvella Therapeutics in Q1 2018 and has held it in 13 quarters since.
  • PNC Financial Services Group's Palvella Therapeutics position peaked at $7K in Q1 2018.
  • 199 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.